Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Imitrex "Authorized" Generic Launch Planned In Q4 2008

This article was originally published in The Pink Sheet Daily

Executive Summary

GlaxoSmithKline and Dr. Reddy's reach settlement agreement on the migraine tablets allowing a generic launch several months prior to patent expiration.
Advertisement

Related Content

Dr Reddy’s Launches Generic Versions Of GSK’s Imitrex; Ranbaxy May Have To Wait
Latest Imitrex Patent Settlement Protects GSK’s “Authorized” Generic
Latest Imitrex Patent Settlement Protects GSK’s “Authorized” Generic
Imitrex Patent Settlement Allows For Entry During Pediatric Exclusivity Period
Imitrex Patent Settlement Allows For Entry During Pediatric Exclusivity Period
GlaxoSmithKline/Pozen Anticipate Mid-2007 Launch For Trexima Migraine Combo
Trexima Approvable Letter Another Headache For Pozen
If You Can't Beat Em'…Merck Signs Authorized Generic Deal For Zocor And Proscar
If You Can't Beat Em'…Merck Signs Authorized Generic Deal For Zocor And Proscar

Topics

Advertisement
UsernamePublicRestriction

Register

PS063166

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel